Alison Moore
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
Allogene CFO Departure Comes Amid CAR-T Sector Safety Concerns. Allogene announced that Chief Financial Officer Geoffrey Parker will retire effective November 6, marking a leadership transition at a challenging time for the company. The timing coincides with broader scrutiny of CAR-T therapies for autoimmune conditions after competing trials from Novartis and Bristol Myers were paused over safety concerns. On the clinical front, the company indicated that if its minimal residual disease data holds, it could represent a significant shift in its business outlook. The stock has traded within a $1.04 to $4.46 range over the past year.
Transaction History
| CDXS | ▼ Sell | Open Market | 3,826 | $5K | 2/6/2026 | View on chart |
| CDXS | ▲ Buy | Grant | 85,000 | $0 | 11/13/2025 | View on chart |
| CDXS | ▼ Sell | Open Market | 6,239 | $16K | 10/13/2025 | View on chart |
| CDXS | ▲ Buy | Grant | 26,875 | $0 | 2/5/2025 | View on chart |
| CDXS | ▲ Buy | Grant | 50,000 | $0 | 10/10/2024 | View on chart |
| CDXS | ▲ Buy | Grant | 30,120 | $0 | 6/11/2024 | View on chart |
| CDXS | ▲ Buy | Grant | 34,602 | $0 | 6/13/2023 | View on chart |
| ALLO | ▲ Buy | Grant | 558,094 | $0 | 3/22/2023 | View on chart |
| ALLO | ▼ Sell | Tax Withholding | 8,351 | $46K | 3/14/2023 | View on chart |
| CDXS | ▲ Buy | Grant | 11,273 | $0 | 6/14/2022 | View on chart |
| ALLO | ▼ Sell | Open Market | 8,698 | $66K | 3/15/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Codexis Signs siRNA Manufacturing Deal
Codexis has entered an agreement with an unnamed siRNA drug innovator to use its ECO Synthesis platform for stereo-defined fragment synthesis. This partnership highlights the company's manufacturing capabilities in a growing therapeutic area. The stock is currently trading near its 52-week low, with recent price action showing rejection at support levels.
Codexis Signs siRNA Manufacturing Deal. Codexis has entered an agreement with an unnamed siRNA drug innovator to use its ECO Synthesis platform for stereo-defined fragment synthesis. This partnership highlights the company's manufacturing capabilities in a growing therapeutic area. The stock is currently trading near its 52-week low, with recent price action showing rejection at support levels.